monARC Bionetworks, a healthcare technology company that has built an end-to-end clinical research platform to facilitate greater collaboration between patients, physicians, and researchers involved in clinical trials, initiated a strategic integration with the drug development platform of Roivant Sciences, a global biopharmaceutical company focused on reducing the time and cost of the drug development process.
monARC’s multi-disciplinary team of drug developers and technology experts have built disease-specific patient network applications and online tools that prequalify and engage patients during protocol development prior to study initiation. They have also developed a suite of digital apps, back-end architecture, and telemedicine capabilities to reduce site visits and enable completely virtual clinical trials.
This integrated platform has been crafted to accelerate patient enrollment, improve site selection, reduce protocol amendments, decrease patient dropout rates, permit rapid experimentation with novel apps and devices, and ensure that individuals in remote and underserved communities can participate in clinical trials. monARC’s current customers include academic researchers, biopharmaceutical companies, and medical device manufacturers.
In a pilot program, monARC’s platforms yielded clinical trial enrollment 20 times faster than industry benchmarks in idiopathic pulmonary fibrosis and ensured 90% adherence from elderly patients using digital data collection tools like Bluetooth-connected spirometers, weight scales, and activity watches.
With Roivant’s strategic investment, monARC can expand its patient research networks into additional diseases including atopic dermatitis, obesity, and diabetes to help meet growing customer and patient demand.
monARC Bionetworks is a US startup company that’s on a mission to modernize the clinical trials / clinical research industry by empowering patients to share their data.
Roivant Sciences is a global biopharmaceutical company focused on reducing the time and cost of the drug development process to improve the lives of patients and their families. Roivant partners with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly delivered to patients.